World's Best Scientists 2026 revealed!
Andy I. M. Hoepelman

Andy I. M. Hoepelman

D-Index & Metrics

Microbiology

D-Index
69
Citations
17787
World Ranking
2034
National Ranking
87

Andy I. M. Hoepelman publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Andy I. M. Hoepelman sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 271 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Andy I. M. Hoepelman D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Andy I. M. Hoepelman sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 69 D-Index — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Andy I. M. Hoepelman is affiliated with Utrecht University in the Netherlands and has conducted extensive research within the fields of Medicine and Immunology and Microbiology. Their work spans a variety of infectious diseases, with a particular focus on clinical and epidemiological aspects.

The main subfields of their research include Infectious Diseases, Epidemiology, Virology, Parasitology, and Neurology. Their studies often explore topics related to HIV research and treatment, HIV/AIDS research and interventions, COVID-19 clinical research studies, vector-borne infectious diseases, HIV/AIDS drug development and treatment, mosquito-borne diseases and control, and the long-term effects of COVID-19.

Some of their recent papers include:

  • Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials, 2021, Nature Communications
  • Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency, 2020, Blood
  • Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials, 2020, bioRxiv (Cold Spring Harbor Laboratory)
  • Dual Antiretroviral Therapy-All Quiet Beneath the Surface?, 2021, Frontiers in Immunology
  • Decreased All-Cause and Liver-Related Mortality Risk in HIV/Hepatitis B Virus Coinfection Coinciding With the Introduction of Tenofovir-Containing Combination Antiretroviral Therapy, 2020, Open Forum Infectious Diseases

Frequent publication venues for their work comprise Clinical Microbiology and Infection, Nature Communications, AIDS, Clinical Infectious Diseases, and Journal of NeuroVirology. These venues reflect their contributions across multiple infectious and immunological disciplines.

They have collaborated with several researchers, demonstrating recurring cooperation with colleagues such as Berend J. van Welzen, Jesper M. Weehuizen, Patrick G. A. Oomen, Peter C. Wever, and Chantal P. Bleeker-Rovers. These collaborations have supported research outputs across various studies.

Best Publications

  • Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

    Devin Razavi-Shearer;Ivane Gamkrelidze;Mindie H Nguyen;Ding-Shinn Chen

  • Immune dysfunction in patients with diabetes mellitus (DM)

    Suzanne E Geerlings;Andy I.M Hoepelman

  • Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.

    L M A J Muller;K J Gorter;Eelko Hak;W L Goudzwaard

  • Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

    Gerd Fätkenheuer;Anton L Pozniak;Margaret A Johnson;Andreas Plettenberg

  • Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management

    Annemarie M. J. Wensing;David A. van de Vijver;Gioacchino Angarano;Birgitta Åsjö

  • Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults

    Douwe F. Postma;Cornelis H. van Werkhoven;Leontine J.R. van Elden;Steven F.T. Thijsen

  • Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

    Gerd Fätkenheuer;Mark Nelson;Adriano Lazzarin;Irina Konourina

  • Clinical Management of Ebola Virus Disease in the United States and Europe.

    Timothy M. Uyeki;Aneesh K. Mehta;Richard T. Davey;Allison M. Liddell

  • Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review

    Roos E Barth;Maarten F Schim van der Loeff;Rob Schuurman;Andy I M Hoepelman

  • Clinical pulmonary infection score for ventilator-associated pneumonia: accuracy and inter-observer variability

    Carolina A. M. Schurink;Christianne A. Van Nieuwenhoven;Jan A. Jacobs;Maja Rozenberg-Arska

  • Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction.

    Leontine J.R. Van Elden;Anton M. Van Loon;Floris Van Alphen;Karin A.W. Hendriksen

  • CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia

    Joris M. van Montfrans;Andy I.M. Hoepelman;Sigrid Otto;Marielle van Gijn

  • A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.

    Unknown

  • Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.

    Cathrine Axfors;Cathrine Axfors;Andreas M. Schmitt;Andreas M. Schmitt;Perrine Janiaud;Janneke van’t Hooft;Janneke van’t Hooft

  • Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.

    Margriet M E Schneider;Jan C C Borleffs;Ronald P Stolk;Christian A J J Jaspers

  • Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection.

    Jan Jelrik Oosterheert;Anton M van Loon;Rob Schuurman;Andy I M Hoepelman

  • Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial

    Jan Jelrik Oosterheert;Marc J M Bonten;Margriet M E Schneider;Erik Buskens

  • Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus.

    Andy I.M. Hoepelman;Ruby Meiland;Suzanne E. Geerlings

  • Plasma vascular endothelial growth factor in severe sepsis.

    Michiel van der Flier;Henk J van Leeuwen;Kok P van Kessel;Jan L Kimpen

  • Consequences of microbial attachment: directing host cell functions with adhesins.

    A. I. M. Hoepelman;E. I. Tuomanen

  • Adherence in antiretroviral therapy: a review of qualitative studies.

    Sigrid C J M Vervoort;Jan C C Borleffs;Andy I M Hoepelman;Mieke H F Grypdonck

  • Acute hepatitis C in HIV-infected individuals : recommendations from the European AIDS Treatment Network (NEAT) consensus conference The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel

    Matthieu Albert;Jose Benito;Sanjay Bhagani;Christoph Boesecke

Frequent Co-Authors

Annemarie M. J. Wensing
Annemarie M. J. Wensing Utrecht University
Eelko Hak
Eelko Hak University of Groningen
Rob Schuurman
Rob Schuurman Utrecht University
Marc J. M. Bonten
Marc J. M. Bonten Utrecht University
Jan Verhoef
Jan Verhoef Utrecht University
Jan M. Prins
Jan M. Prins University of Amsterdam
Charles A. Boucher
Charles A. Boucher Erasmus University Rotterdam
Debbie van Baarle
Debbie van Baarle University Medical Center Groningen
Ronald P. Stolk
Ronald P. Stolk University Medical Center Groningen
Kees Brinkman
Kees Brinkman University of Amsterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to various online degrees that complement and expand career opportunities. For those interested in healthcare, exploring what medical degrees can I get online is a great starting point to understand accessible programs that offer flexibility without compromising quality.

If public health interests you, many students opt for a Master of Public Health (MPH). To ease entry into this field, researching the easiest mph online programs to get into can help find accommodating programs tailored to diverse backgrounds and schedules.

Career pathways may also include specialized roles like becoming a child life specialist. Knowing details such as how much do child life specialists make provides insight into the profession’s value and sustainability.

Accessibility to higher education is crucial. For individuals with unique challenges, including those looking into college degrees for felons, there are supportive online degrees that encourage second chances and career growth in fields related to microbiology and beyond.

Best Scientists Citing Andy I. M. Hoepelman

Trending Scientists

Recently Published Articles